Neowise (新景智源生物科技) focuses on the discovery and development of TCR-T immunotherapies aimed at solid tumors. The company has built a proprietary high-throughput, high-sensitivity target-antigen/TCR discovery platform (CAST®) that combines AI computation with experimental validation to rapidly identify high-affinity, tumor-specific TCR sequences. Its lead candidate, NW-101C, targets PRAME and is the first domestic therapy against this antigen to reach clinical trials, currently in a Phase I registration study across multiple late-stage solid tumors. A second candidate, NW-301V, targets the KRAS G12V mutation and delivered an objective response rate of 50% and a disease control rate of 100% in an early trial involving 14 evaluable colorectal and pancreatic cancer patients, with no dose-limiting toxicities observed. Over the past two years the company has advanced two programs into the clinic, validating its platform capabilities. Proceeds from the latest financing will fund further clinical development of these core assets and advance multiple preclinical programs, while supporting commercialization and international expansion efforts. The firm has received continued backing from existing investors alongside new institutional support, underscoring confidence in its pipeline and platform.

Total raised

$58M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026